SCHEMBL5886979

SCHEMBL5886979

Cc1nc(N2CCN(C(=O)Cc3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.44
MAPT P10636 4/20 0.41
TP53 P04637 1/20 0.41
ALDH1A1 P00352 5/20 0.40
ME2 P23368 1/20 0.40
ME1 P48163 1/20 0.40
ME3 Q16798 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 1/20 0.39
MEN1 O00255 2/20 0.39
CYP2C19 P33261 1/20 0.39
MMP13 P45452 2/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 3/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
MMP2 P08253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887019 0.95 ALDH1A1 (0.41) GBA1MAPTTP53ALDH1A1HPGD
SCHEMBL5886912 0.94 ME2 (0.43) GBA1ALDH1A1ME2ME1ME3
SCHEMBL5887151 0.93 GBA1 (0.39) GBA1MAPTTP53ALDH1A1HPGD
SCHEMBL5886882 0.93 MAPT (0.43) MAPTTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL5887394 0.92 ACHE (0.44) MAPTTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL5887675 0.91 SLC6A7 (0.44) GBA1MAPTTP53ALDH1A1SMN1; SMN2
SCHEMBL5886891 0.91 TP53 (0.44) MAPTTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL5887021 0.91 SMN1; SMN2 (0.45) MAPTALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL5887548 0.90 KMT2A (0.46) MAPTTP53ALDH1A1HSD17B10KMT2A
SCHEMBL5886779 0.90 MAPT (0.44) MAPTTP53ALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP GBA1 4528/4885MAPT 1614/4885TP53 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.